Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma Feb 8, 2018
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting Feb 5, 2018
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™) Jan 29, 2018
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting Jan 22, 2018
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting Jan 18, 2018
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer Jan 4, 2018
Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium Dec 11, 2017
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer Nov 8, 2017
